The goal of the present study was to investigate this parameter as a marker for risk of progression in MGUS (n=407) and SMM (n=93). Patients with a marked predominance of aPC/BMPC (≥95%) at diagnosis displayed a significantly higher risk of progression both in MGUS and SMM (p< 0.001). Multivariate analysis for progression free survival (PFS) selected the % aPC/BMPC (≥95%) as the most important independent variable in both entities, together with DNA aneuploidy and immunoparesis for MGUS and SMM, respectively. Using these independent variables, we have identified three risk categories in MGUS (PFS at 5 years of 2%, 10% and 46%, respectively (p<0.001)) and SMM patients (PFS at 5 years of 4%, 46%, and 72%, respectively (p<0.001)). Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that could help to individualize the follow-up strategy for MGUS and SMM patients.
ABSTRACT

Monoclonal gammopathy of uncertain significance (MGUS) and smoldering Multiple
Myeloma (SMM) are plasma cell disorders with a risk of progression around 1% and 10% per year, respectively. We have previously shown that the proportion of BM aberrant plasma cells within the BMPC (bone marrow plasma cell) compartment (aPC/BMPC) assessed by FlowCytometry contribute to differential diagnosis between MGUS and MM.
The goal of the present study was to investigate this parameter as a marker for risk of progression in MGUS (n=407) and SMM (n=93). Patients with a marked predominance of aPC/BMPC (≥95%) at diagnosis displayed a significantly higher risk of progression both in MGUS and SMM (p< 0.001). Multivariate analysis for progression free survival (PFS) selected the % aPC/BMPC (≥95%) as the most important independent variable in both entities, together with DNA aneuploidy and immunoparesis for MGUS and SMM, respectively. Using these independent variables, we have identified three risk categories in MGUS (PFS at 5 years of 2%, 10% and 46%, respectively (p<0.001)) and SMM patients (PFS at 5 years of 4%, 46%, and 72%, respectively (p<0.001)). Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that could help to individualize the follow-up strategy for MGUS and SMM patients.
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INTRODUCTION
Monoclonal gammopathy of uncertain significance (MGUS) and Smoldering multiple myeloma (SMM) represent two forms of asymptomatic plasma cell disorder that share in common a variable period of stable disease but which may eventually progress to symptomatic Multiple Myeloma (MM). MGUS is the most common plasma cell disorder, whose incidence increases with age, affecting approximately 3% of population over 50 years of age and up to 10% in those over 70 years [1] [2] [3] . Diagnosis of MGUS is characterized by the presence of a monoclonal immunoglobulin in serum ≤ 3 g/dl, and a < 10% of plasma cells in bone marrow, in the absence of end-organ damage, related to the proliferation of monoclonal plasma cell 1, 2, 4 . Smoldering multiple myeloma (SMM) is also an asymptomatic plasma cell disorder that fulfills the diagnostic criteria of multiple myeloma (MM), although it is characterized by the absence of lytic lesions, anemia, renal insufficiency or hypercalcemia (CRAB symptoms) 2 . Its estimated prevalence ranges from 15% to 44% of newly diagnosed MM 1, 5, 6 .
When progression occurs, the majority of cases evolve to overt MM. The rate of progression is significantly lower for MGUS cases (around 1% per year 7 ) than for SMM (10% per year   8 ). Therefore, a different follow-up strategy is needed in these two groups of monoclonal plasma cell disorders, with a closer follow-up in SMM than in MGUS.
However, it would be most valuable to have individualized information on factors associated with the risk of progression at diagnosis in order to determine patient follow-up strategy according to their individual risk of progression. For both entities these factors include the amount of monoclonal component, the presence of Bence-Jones proteinuria, the isotype of the monoclonal immunoglobulin (IgA), and an abnormal serum free light-chain ratio 1, 4, 5, [8] [9] [10] [11] . Particularly in the case of SMM, the current standard of care is close follow-up 
MATERIAL & METHODS
Patients
Immunophenotypic Studies
Immunophenotypic analyses were performed on erythrocyte-lysed K 3 -EDTA anticoagulated whole BM samples. A total of 2×10 6 cells/tube were stained-lysed-and-thenwashed using a direct immunofluorescence technique and multicolour staining, aimed at the specific identification and immunophenotypic characterization of PC: CD38-FITC/ CD56-PE/ CD19-PerCP-Cy5/ CD45-APC). In specific cases additional staining for cytoplasmatic
Ig light chains were used to clarify the polyclonal vs. monoclonal nature of PC. The cIgKappa/ cIgLambda staining was performed in a four colour tube including simultaneous surface staining for CD38 plus either CD45 or CD56 or CD19 depending on the type of antigenic aberrancy. All monoclonal antibodies used were purchased from Becton/Dickinson, Biosciences, BDB, San José, CA, except for CD38-FITC (Caltag Laboratories, San Francisco CA), and CD19-PE-Cy5 (Immunotech, Marseille, France).
Acquisition was performed in a FACSCalibur flow cytometer (BDB) using double-step
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From procedure using with the CellQUEST software (BDB). In the first step, a total of 20x10 3 events from the total BM cellularity were measured; in the second step, information on a minimum of 3×10 5 cells were acquired and stored through an electronic "live-gate" drawn on the SSC/CD38 ++ events where PCs are included ( Figure 1 ). In cases with very low numbers of PC the acquisition of cells was increased in order to reach the minimum target of PC events (≥1000). We first identified PC based on the expression of CD138/high expression of CD38 with and interm SCC. Once PC were identified, we focused our analysis on the PC compartment, and within it, we discriminated between PC with a normal and aberrant phenotype (polyclonal and clonal PC, respectively) [21] [22] [23] . For this purpose, we used a validated immunophenotypic approach 23, 24 where the absence of CD19 and/or CD45, the decreased expression of CD38 and over expression of CD56 were used for the identification of aberrant phenotypes on PC (Table 2 ). For each case analysed data recorded were: i) total percentage of PCs from the whole nucleated BM celullarity and; ii)
percentage of abnormal plasma cells (aPC) within the BM PC compartment. The latter parameter will be referred to in the text as: aPC/BMPC.
DNA index assessed by flow cytometry was performed using a double-staining procedure for nuclear DNA (with propidium iodide) and surface antigens (with anti-CD38 plus anti-CD138 monoclonal antibodies) as previously described 25 , and the analysis was performed specifically on the PC (CD38 plus CD138+) cells. Aneuploidy was defined as hypo and hyperdiploidy bases on flow cytometry assessment.
The analysis by FC and the evaluation of the disease status, including the decision that therapy was needed, were performed by independent observers.
Statistical analyses
The Chi square and the Mann-Whitney U tests were used to estimate the statistical significance of differences observed between groups. Survival curves were plotted according to the Kaplan and Meier method, using log-rank and Breslow tests for comparison. In the univariate analysis for progression free survival (PFS), the following variables were tested: age, sex, hemoglobin, heavy chain, light chain, amount of MC, renal function, % of BMPC by optical microscope, % of BMPC by multiparameter FC, % of aPC/BMPC, presence of immunoparesis, DNA ploidy, and presence of Bence-Jones proteinuria. Multivariate analysis 15 was performed to explore the independent effect of variables that showed a significant influence on progression free survival in the univariate analysis. The Cox regression model that was used employed the stepwise methods "forward conditional" as the variable selection model. Quantitative parameters were considered both as continuous as well as dichotomic variables.
All statistical analyses were performed using SPSS software -12.5 versions -(SPSS Inc.
Chicago, IL,).
RESULTS:
The clinical and biological characteristics of MGUS and SMM patients analyzed are summarized in Table 1 . Median age (70 years) at diagnosis and sex distribution was similar in both groups. The frequency of IgG paraprotein was slightly higher in MGUS than in SMM (75% vs. 64%) while the opposite figure was observed for IgA (21% vs. 34%). The median value of the serum MC was 1.6 g/dL (range: 0.3 to 3.0 g/dL) and 2.37 g/dL (range:
0.8 to 6.5) for MGUS and SMM, respectively. The light chain was kappa in 73% (n=298) of the cases of MGUS patients and in 65% of SMM cases. Immunoparesis was present in 25% of MGUS patients (18% had decreased levels of only one Ig and 7% had low levels of two Igs) and in 52% of SMM patients (22% of one Ig and 30% of both chains). Bence
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Jones proteinuria was detected in 40 (17%) MGUS and 14 (22%) SMM patients. The median percentage of bone marrow plasma cell PC (BMPC) by conventional morphology was 4% and 14% in MGUS and SMM, respectively.
As expected, multiparameter FC showed lower percentages of BM PC than morphology, probably due to a dilutional effect. The median value of PC infiltration by FC was significantly higher in patients with SMM than in MGUS (median 2.9% vs. 1.0%, p<0.001). When the analysis was restricted to the PC compartment and we discriminated between normal and phenotypically aberrant PC (aPC) (clonal PC), we observed that, in SMM, aberrant PC markedly predominate (median 97% aPC from the total BMPC cellularity) while in MGUS the distribution of abnormal/normal PC is more balanced, with 73% of PC displaying an aberrant phenotype. Moreover, if we consider the cut-off value of > 95%aPC/BMPC which was previously used for differential diagnosis between MGUS and MM (it should be remembered that in symptomatic MM almost all PC (≥95%) display an aberrant phenotype), we observed that while 60% of SMM were above this threshold, only 18% of MGUS had ≥ 95% aPC (p<0.001).
Interestingly, the percentage of phenotypically aPC/BMPC at diagnosis allowed the discrimination of two groups of patients with significantly different risks of progression to overt MM, both in MGUS and in SMM patients. Thus, in the MGUS group, 24% of patients (18/73) with more than 95% aPC/BMPC progressed with a median time to progression of 107 months, while only 4% (15/330) patients progressed in the group of cases with less than 95% of aPC/BMPC (p< 0.001), with a cumulative probability of progression at 5 years of 25% vs. 5% respectively (Figure 2a) . Similarly, within SMM patients the rate of progression to symptomatic MM for cases with > or < of 95% aPC/BMPC was 63% (36/56) vs. 10% (4/37) (p< 0.001) (Figure 2b 
org From probability of progression at 5 years of 64% vs. 8%, respectively.
Other factors associated with a significant impact on progression free survival (PFS) in both groups of patients were: bone marrow plasma cells infiltration by conventional morphology (p<0.002), overall percentage of PC evaluated by flow cytometry (p<0.01), and immunoparesis (p<0.001) ( Table 3 ). In addition, in MGUS patients, a Bence-Jones proteinuria higher than 0.2g /24 hours (p< 0.001), DNA aneuploidy (p= 0.01) and MC levels ≥ 2gr/dl (p<0.001) also had significant impact on PFS (Table 3) . Other variables such as gender, isotype of the MC Ig, β 2 -microglobulin serum levels, ESR, haemoglobin, C reactive-protein were not associated with a different incidence of disease progression.
Interestingly, when we focused on patients with low risk of progression based on conventional criteria, such as low amounts of MC (<2 g/dl for MGUS and < 3g/dl for SMM) or the absence of immunoparesis, the evaluation of the percentage of aPC/BMPC still allowed the discrimination of two groups of patients at different risks of progression.
Thus, among cases with low MC, those patients with ≥ 95% aPC/BMPC showed lower PFS than those with <95% aPC/BMPC, with significant impact on MGUS (p< 0.002) as well as SMM (p<0.001) (Figure 3 ). In the same way, upon restricting analysis to patients with no immunoparesis, cases with ≥ 95% of aPC/BMPC had poor prognosis in both diagnostic categories (SMM and MGUS) (p<0.02) (Figure 3) . Similarly, the presence of ≥ or < 95% aPC/BMPC was able to discriminate two prognostic subgroups within patients with high BMPC infiltration or high MC in MGUS as well as SMM patients (data not shown).
In order to explore whether or not the percentage of immunophenotypically aPC/BMPC evaluated by FC was an independent prognostic factor for PFS among MGUS and SMM patients, a multivariate analysis was performed. Interestingly, in both diagnostic groups the sole common variable with independent prognostic value for PFS was the aPC/BMPC For personal use only. on September 14, 2017. by guest www.bloodjournal.org From (p<0.001 for MGUS and p=0.003 for SMM patients). In the MGUS group the DNA index also had independent prognostic value (p=0.001), with a risk of progression increased by a factor 8.2 in cases with ≥ 95% of aPC/BMPC, and by 4.6 in patients with DNA aneuploidy.
In contrast, for the SMM patients, presence of immunoparesis was selected as also having independent prognostic value for PFS (p=0.02), with a risk of progression to symptomatic MM increased by a factor of 5.4 in cases with ≥ 95% of aPC/BMPC, and by 2.5 in patients with low levels of one or more uninvolved immunoglobulin at diagnosis.
Based on variables with independent prognostic value for MGUS transformation (≥95% aPC/BMPC and DNA aneuploidy) we established a prognostic index, by assigning one point for each adverse factor. Accordingly, three risk groups of MGUS patients were defined: cases with no risk factors (PFS at 5 years of 2%), cases with one risk factor (10% PFS at 5 years) and patients with both risk factors (46%PFS at 5 years). The same approach was used for SMM (but now based on ≥ 95% aPC/BMPC and immunoparesis). The PFS at 5 years was 4%, 46% and 72% for patients with none, one, or two risk factors, respectively (p<0.001) (Figure 4b ).
DISCUSSION
The term MGUS, introduced by Kyle more than 25 years ago 26 . Thus, the over expression of CD56 together with the absence of reactivity for CD19 and for CD45 and/or decreased amounts of CD38 have been found to be common characteristics of MM plasma cells 12, 18, 34 . Such aberrant phenotypes of BM plasma cells have been used for the study of minimal residual disease in MM, and it has been suggested that the persistence of immunophenotypically abnormal PC in the BM after treatment is associated with a worse clinical outcome 13, [21] [22] [23] 35 . In addition,
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we have shown that the proportion of aPC/BMPC was the most important criteria for differential diagnosis between MGUS and MM patients 12 . Nevertheless, up until now the potential value of PC immunophenotypic investigation for predicting the risk of progression of MGUS and SMM patients has not been explored. Based on this background, we wanted to investigate the potential impact of the detection of aPC/BMPC on the risk of transformation of MGUS and SMM into symptomatic disease. In our study, at five years, the risk of progression was 25% and 64% respectively for MGUS and SMM cases in which the vast majority of PC have an aberrant phenotype (≥95% aPC/BMPC). These figures are clearly higher than those of patients with <95% aPC/BMPC, in which the risk of progression at five years is 5% and 8% for the MGUS and SMM group, respectively. It should be emphasized that the immunophenotypic strategy used here is very simple and cost-effective, since it only requires a tube sample with four monoclonal antibodies which results in low cost.
Based on the two parameters with independent value in the multivariate analysis (≥95% aPC/BMPC, and DNA aneuploidy for MGUS, and ≥ 95% aPC/BMPC, and presence of immunoparesis for SMM), we propose a simple scoring system, assigning 1 point to each adverse variable, which allows prognostic stratification of MGUS and SMM patients at diagnosis into the three risk categories. The cumulative probability of progression from MGUS to MM at five years was significantly different for the 3 subgroups: 2%, 10% and 46%, respectively. A similar pattern was observed for SMM with a risk of progression to symptomatic disease at 5 yeas of 4%, 46% and 72%, respectively, for patients with none, one or two risk factors. As mentioned above, the Mayo Clinic group has recently proposed a new risk classification based on free light chain measurements 11 . Of particular interest would be to prospectively explore whether free light chain and % aPC represent In summary, in the present study we show that multiparameter FC evaluation of BMPC at diagnosis of MGUS and SMM is a valuable tool for predicting the risk of progression to overt MM, since it allows the identification of patients at high risk of early progression (those in which the vast majority of PC display an aberrant phenotype), which may benefit from early treatment interventions, as opposed to a group of patients (in which both, aberrant and normal PC coexist) who will likely be free of progression for a long period of time and could be safely monitored without treatment over many years. Results expressed as median and (range) or as * number of cases (percentage). * cut-off point of bone marrow plasma cell infiltration of 5% for MGUS and 15% for SMM.
** cut-off point of bone marrow plasma cell infiltration by flow cytometry of 1% for MGUS and 5% for SMM. 
